Vanqua Bio
Catherine Lammert, Ph.D. has a comprehensive work experience in the field of neuroscience. From 2013 to 2015, they worked as a Research Assistant II at The Jackson Laboratory, where they modeled human neurodegenerative disease in mice. From 2015 to 2020, they were a PhD Student at the University of Virginia School of Medicine, where they investigated how AIM2 inflammasome activation in the CNS shapes neurodevelopment and behavior, defined roles for microbiota-mediated regulation of inflammation in a maternal immune activation model of autism, and investigated how dysregulated IL-1 signaling during gestation contributes to altered brain maturation and the development of autistic phenotypes. From 2018 to 2020, they also served as a Graduate Student representative to the University of Virginia Neuroscience Graduate Program Admissions Committee, and from 2016 to 2018, they were the Graduate Student representative for the Neuroscience Graduate Program in the Graduate Biosciences Society. Currently, they are a Postdoctoral Researcher at Northwestern University - The Feinberg School of Medicine, and in 2022 they will become a Senior Scientist at Vanqua Bio.
Catherine Lammert, Ph.D. obtained their Doctor of Philosophy - PhD in Neuroimmunology from the University of Virginia between 2015 and 2020. Prior to that, they obtained their Bachelor of Science - BS in Neuroscience from Stonehill College between 2008 and 2012.
Vanqua Bio
Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD).